This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019;49(4):328-330.

doi: 10.1159/000499598. Epub 2019 Mar 28.

Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease

Kevin D Burns¹, David Cherney^{2

3

4}

Affiliations

Affiliations

¹ Division of Nephrology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
² Division of Nephrology, University of Toronto, Toronto, Ontario, Canada, david.cherney@uhn.ca.
³ Department of Physiology, University of Toronto, Toronto, Ontario, Canada, david.cherney@uhn.ca.
⁴ Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada, david.cherney@uhn.ca.

PMID: 30921790
DOI: 10.1159/000499598

Free article

Editorial

Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease

Kevin D Burns et al. Am J Nephrol. 2019.

Free article

. 2019;49(4):328-330.

doi: 10.1159/000499598. Epub 2019 Mar 28.

Authors

Kevin D Burns¹, David Cherney^{2

3

4}

Affiliations

¹ Division of Nephrology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
² Division of Nephrology, University of Toronto, Toronto, Ontario, Canada, david.cherney@uhn.ca.
³ Department of Physiology, University of Toronto, Toronto, Ontario, Canada, david.cherney@uhn.ca.
⁴ Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada, david.cherney@uhn.ca.

PMID: 30921790
DOI: 10.1159/000499598

No abstract available

PubMed Disclaimer

Comment on

Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG. Woods TC, et al. Am J Nephrol. 2019;49(4):331-342. doi: 10.1159/000499597. Epub 2019 Mar 28. Am J Nephrol. 2019. PMID: 30921791 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

CIHR/Canada

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- S. Karger AG, Basel, Switzerland
Medical
- MedlinePlus Health Information